AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ANGO
Previous Symbol
CUSIP03475V10
Phone518-795-1400
Debt
Debt-to-Equity Ratio0.16
Current Ratio2.64
Quick Ratio1.55
Price-To-Earnings
Trailing P/E Ratio29.34
Forward P/E Ratio25.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$344.29 million
Price / Sales2.34
Cash Flow$1.4531 per share
Price / Cash14.94
Book Value$14.74 per share
Price / Book1.47
Profitability
EPS (Most Recent Fiscal Year)$0.74
Net Income$16.33 million
Net Margins4.62%
Return on Equity5.44%
Return on Assets4.18%
Miscellaneous
Employees1,145
Outstanding Shares37,120,000
Market Cap$764.71 million
OptionableOptionable
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings results on Thursday, September, 27th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.02. The medical instruments supplier had revenue of $85.34 million for the quarter, compared to the consensus estimate of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The company's revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the business earned $0.13 earnings per share. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics issued an update on its FY19 earnings guidance on Thursday, September, 27th. The company provided earnings per share guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.85. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $350.34 million.
What price target have analysts set for ANGO?
4 analysts have issued 12 month target prices for AngioDynamics' shares. Their predictions range from $16.33 to $20.00. On average, they anticipate AngioDynamics' share price to reach $18.1650 in the next twelve months. This suggests that the stock has a possible downside of 16.3%. View Analyst Price Targets for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.
Has AngioDynamics been receiving favorable news coverage?
News coverage about ANGO stock has been trending neutral on Saturday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AngioDynamics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), K2M Group (KTWO), AtriCure (ATRC), Nevro (NVRO), Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), Cryolife (CRY) and Cardiovascular Systems (CSII).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, CEO, Pres & Director (Age 54)
- Mr. Michael C. Greiner, Exec. VP & CFO (Age 45)
- Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 54)
- Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
- Mr. Robert A. Simpson, Sr. VP & GM of Peripheral Vascular Global Bus. Unit (Age 46)
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.52%), Dimensional Fund Advisors LP (8.41%), Janus Henderson Group PLC (4.30%), Wells Fargo & Company MN (2.97%), Victory Capital Management Inc. (2.74%) and Royce & Associates LP (2.08%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, James C Clemmer, Jan Stern Reed and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.
Which institutional investors are selling AngioDynamics stock?
ANGO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Panagora Asset Management Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Tributary Capital Management LLC, Prudential Financial Inc., Alambic Investment Management L.P. and Lapides Asset Management LLC. View Insider Buying and Selling for AngioDynamics.
Which institutional investors are buying AngioDynamics stock?
ANGO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Heartland Advisors Inc., Tributary Capital Management LLC, WINTON GROUP Ltd, Virginia Retirement Systems ET AL, Nordea Investment Management AB and Acadian Asset Management LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $21.71.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $764.71 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe.
What is AngioDynamics' official website?
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
